BioNxt Accelerates R&D with Move to Gen-Plus Laboratory in Munich, Germany, Expanding Drug Delivery Research Capabilities
21.1.2025 03:05:00 CET | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESS Newswire / January 21, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, is excited to announce a major milestone in its research and development journey. The company is transitioning its cutting-edge R&D activities to the Gen-Plus Contract Research and Development Organization (CRDO) in Munich, Germany, with operations scheduled to begin on March 1, 2025. This move underscores BioNxt's commitment to scientific innovation and advancing solutions for unmet medical needs.
The new laboratory facility provides BioNxt with access to cutting-edge technologies, an expanded 1,000-square-meter research environment, and strategic opportunities for scientific collaboration within Europe's biotech hub. The transition is expected to accelerate the company's ongoing projects, particularly in the areas of drug delivery systems, neurodegenerative disease therapeutics, and next-generation biomedical technologies.
BioNxt Relocates to Gen-Plus: Strategic Importance for Advanced R&D
By leveraging the advanced and innovative infrastructure of the Gen-Plus Laboratory, BioNxt aims to harness the facility's 1,000 square meters of state-of-the-art space designed for high-potency active pharmaceutical ingredients and GMP-compliant processes. The lab's specialized equipment, including advanced technologies for solid and semi-solid dosage forms and capabilities in drug printing, will empower BioNxt to:
Enhance R&D Capabilities: With access to cutting-edge equipment and analytical tools, BioNxt is better positioned to develop innovative solutions and optimize its research outcomes.
Foster Collaborations: The Munich location enables proximity to leading research institutions, biotech firms, and academic experts, paving the way for impactful partnerships.
Accelerate Innovation: The advanced resources at Gen-Plus Laboratory allow BioNxt to streamline workflows and reduce the time to bring groundbreaking therapies to market.
"BioNxt's transition to Gen-Plus marks a pivotal moment for BioNxt," said Hugh Rogers, CEO of BioNxt Solutions Inc. "This transition is both strategic and timely, and unlocking new possibilities for added strength on IP with innovation and reinforcing our mission to deliver transformative therapies for patients worldwide. We are thrilled about the opportunities that this new chapter brings, providing Impact on Current and Future projects."
BioNxt's innovative projects, including the development of advanced drug delivery systems such as sublingual thin films, transdermal patches, and other targeted therapeutic platforms, stand to gain significant advantages from the advanced capabilities at the Gen-Plus Laboratory. This cutting-edge facility is poised to accelerate preclinical research timelines, enhance formulation accuracy, and streamline the development of next-generation therapeutics.
About Gen-Plus GmbH & Co. KG
Gen-Plus GmbH & Co. KG, headquartered in Munich, Germany, is a premier Contract Research and Development Organization (CRDO) with over 25 years of experience in pharmaceutical formulation and development. The company operates a 1,000-square-meter state-of-the-art laboratory equipped for handling high-potency active pharmaceutical ingredients and licensed for GMP-compliant production, including narcotics.
Gen-Plus specializes in developing solid and semi-solid dosage forms, transdermal patches, and oral thin films, offering end-to-end services from feasibility studies to clinical trial supply production. The company leverages advanced technologies such as hot-melt extrusion, drug printing, and amorphization of APIs to deliver comprehensive pharmaceutical solutions.
Committed to innovation, Gen-Plus collaborates with leading European research institutions and biotech companies to drive advancements in pharmaceutical solutions. The company's expertise and cutting-edge infrastructure make it a trusted partner in accelerating drug development and commercialization.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information is based on management's expectations, estimates, projections, and assumptions as of the date of this press release. It is subject to significant risks, uncertainties, and other factors that could cause actual results or events to differ materially from those expressed or implied. These risks and uncertainties include, but are not limited to, general economic conditions, market conditions, regulatory risks, technological advancements, and other factors described in the Company's public disclosure filings.
Readers are cautioned not to place undue reliance on forward-looking information, as actual outcomes may differ significantly from those expressed or implied, due to various factors beyond the Company's control. The Company undertakes no obligation to update or revise any forward-looking information, except as required by law.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Loar Holdings Inc. Reports Q4 2025 and Full Year 2025 Record Results, and Upward Revisions to Full Year 2026 Outlook26.2.2026 14:30:00 CET | Press release
WHITE PLAINS, NY / ACCESS Newswire / February 26, 2026 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our"), reports record results for the fourth quarter and full year of 2025 and upward revisions to the full year 2026 outlook. "As we close the year, I am pleased to report that Loar once again delivered record results across key financial metrics, including Net Sales, Adjusted EBITDA, and Adjusted EBITDA Margin," said Dirkson Charles, Loar CEO and Executive Co‑Chairman of the Board of Directors. "Driven by favorable end‑market dynamics and disciplined execution across the organization, our team delivered strong operating performance while advancing our long‑term value creation strategy. These results underscore the scalability and resilience of our business model and reinforce Loar's position as a leading aerospace and defense component supplier. We also successfully completed the acquisitions of LMB Fans & Motors and Harper Engineering, further strengthening
U.S. Polo Assn. Returns as Official Apparel and Jersey Sponsor of the 2026 Dubai Polo Gold Cup for Third Consecutive Year26.2.2026 13:00:00 CET | Press release
WEST PALM BEACH, FL AND DUBAI, UAE / ACCESS Newswire / February 26, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly served as the Official Apparel and Jersey Sponsor of the 2026 Dubai Polo Gold Cup, held January 28 through February 14 at the renowned Al Habtoor Polo Club in Dubai, United Arab Emirates.Dubai Wolves by Thera with their trophy on stage at the Dubai Polo Gold Cup 2026 at the Al Habtoor Polo Club Photo Credit: Margarita Crotto Now marking its third consecutive year supporting the prestigious tournament, U.S. Polo Assn. provided custom performance jerseys to participating teams, apparel for event staff, and exclusive player prizes for the finalists. Spectators joined in the excitement during the traditional divot stomp with a special U.S. Polo Assn. cap giveaway, adding a spirited fan moment to the two-week competition in the UAE. The 2026 Dubai Polo Gold Cup Final delivered an electrifying showdown of world-renowned pl
Innovation Holds Key to Future Growth, New Research from Ipsos, Alchemy-RX and Market Logic Finds26.2.2026 10:00:00 CET | Press release
Global organisations are doubling down on innovation and consumer understanding, as they look to grow revenues in the next three years. LONDON, UK / ACCESS Newswire / February 26, 2026 / A new study, Innovation Reignited: C-Suite insights on the state of innovation, from Ipsos, Alchemy-RX and Market Logic reveals that innovation is rapidly becoming the cornerstone of corporate growth strategies worldwide. According to the findings of the survey of C-Suite executives, 82% of companies expect innovation to drive growth strategy. Still, only the most ambitious leaders (33%) anticipate this will account for more than 20% of revenue in the next three years. However, with respondents reporting that less than 75% of innovation launches meet all their launch goals, the risk of missing ambitious growth targets is significant for those who do not optimise their innovation processes. Deeper customer understanding is key While the need to adopt a customer-centric approach to every stage of innovat
Telestream Advances Production-Ready AI Across Its Product Portfolio26.2.2026 09:00:00 CET | Press release
New AI capabilities drive smarter automation, enriched metadata, and assisted workflow design for live and file-based workflows on-premises and in the cloud NEVADA CITY, CA / ACCESS Newswire / February 26, 2026 / Telestream, global leader in media workflow technologies, today announced expanded practical AI enhancements across its Vantage, Vantage Cloud, EDC, Stanza, and Qualify product lines. Building on the foundation introduced with Vantage AI in 2025, Telestream is advancing its production-ready AI workflows, accelerating localization, strengthening quality control, and introducing new AI-assisted workflow design capabilities that connect and unify enterprise operations across on-premises, cloud, and hybrid environments. The latest enhancements reflect a shift from introducing AI features to operationalizing AI across the enterprise, driving measurable workflow impact across ingest, processing, compliance, and delivery. "Last year we introduced Vantage AI as a new foundation for in
Tech "Talent Wars" Are Over as More Companies Prioritize Upskilling, General Assembly Report Finds25.2.2026 15:00:00 CET | Press release
83% of tech recruiters believe company success is more dependent on upskilling employees for AI versus hiring new talent, according to The State of Tech Talent 2026 NEW YORK CITY, NY / ACCESS Newswire / February 25, 2026 / Nearly all technology recruiters (96%) say technical roles are still at least a bit difficult to fill, as most (83%) believe their company's success is now more dependent on upskilling their existing employees for AI rather than hiring external talent, according to The State of Tech Talent 2026, the fourth annual report from AI training provider General Assembly, an LHH brand. "The AI skills gap is growing too fast for companies to hire their way out," said Daniele Grassi, CEO of General Assembly. "Continuous, incremental and role-specific learning is the only way to keep up with the pace of technology change. Growing investment in upskilling reflects leaders' realization that their existing employees bring the business context, institutional knowledge and cultural n
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom